Receptors and ligands role in colon physiology and pathology

References

• Kadowaki M, Takeda M, Tokita K, et al. Molecular identification and pharmacological characterization of adenosine receptors in the guinea pig colon. Br J Pharmacol 2000;129:871–6
   Google Scholar
• Bielefeldt K, Conklin JL. Intestinal motility during hypoxia and reoxygenation in vitro. Dig Dis Sci 1997;42:878–84
   Google Scholar
• Corbett AD, Lees GM. Depressant effects of hypoxia and hypoglycaemia on neuro-effector transmission of guinea-pig intestine studied in vitro with a pharmacological model. Br J Pharmacol 1997;120:107–15
   Google Scholar
• Greenwald DA, Brandt LJ. Colonic ischemia. J Clin Gastroenterol 1998;27:122–8
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Endo H, Tomimoto A, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008;57:1531–8
   PubMed Web of Science ®Google Scholar
• Yoneda K, Tomimoto A, Endo H, et al. Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. Oncol Rep 2008;20:479–83
   PubMedGoogle Scholar
• Whitfield JF, Chakravarthy B. Calcium: the grand-master cell signaler. Ottawa: NRC Research Press; 2001
   Google Scholar
• Whitfield JF, Bird RP, Chakravarthy BR, et al. Calcium: cell cycle regulator, differentiator, killer, chemopreventor, and may be, tumor promoter. J Cell Biochem 1995;22:74–91
   Google Scholar
• Cianchi F, Papucci L, Schiavone N. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor a-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res 2008;14:7691–700
   PubMed Web of Science ®Google Scholar
• Esfandyari T, Camilleri M, Busciglio I, et al. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007;293:G137–45
   PubMed Web of Science ®Google Scholar
• Coffin B, Fossati S, Flourie B, et al. Regional effects of cholecystokinin octapeptide on colonic phasic and tonic motility in healthy humans. Am J Physiol 1999;276:G767–72
   Google Scholar
• Morton MF, Harper EA, Tavares IA, Shankley NP. Pharmacological evidence for putative CCK1 receptor heterogeneity in human colon smooth muscle. Brit J Pharmacol 2002;136:873–82
   Google Scholar
• Kopp R, Rothbauer E, Ruge M. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 2003;162:115–32
   PubMedGoogle Scholar
• Takahiro K, Yoshitaka T, Toshiki S, et al. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochem Biophys Acta 1999;1438:120–30
   Google Scholar
• Herath NI, Boyd AW. The role of Eph receptors and ephrin ligands in colorectal cancer. Int J Cancer 2010;126:2003–11
   Google Scholar
• Batlle E, Henderson JT, Beghtel H, et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002;111:251–63
   PubMed Web of Science ®Google Scholar
• Kosinski C, Li VS, Chan AS, et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 2007;104:15418–23
   PubMedGoogle Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445–59
   PubMed Web of Science ®Google Scholar
• Thomas SM, Coppelli FM, Wells A, et al. Epidermal growth factor receptor-stimulated activation of phospholipase C gamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res 2003;63:5629–35
   PubMed Web of Science ®Google Scholar
• Wu WKK, Tse TTM, Sung JJY, et al. Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Res 2009;29:229–34
   Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040–8
   PubMed Web of Science ®Google Scholar
• Wong NA, Malcomson RD, Jodrell DI, et al. ERβ isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 2005;207:53–60
   PubMedGoogle Scholar
• Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res 2001;61:632–40
   PubMed Web of Science ®Google Scholar
• Marino M, Galluzzo P. Estrogen receptor β mediates the protective effects of estrogen in colon cancer. Cancer Therapy 2008;6:149–62
   Google Scholar
• Gadaleta RM, Van Mil SW, Oldenburg B, et al. Bile acids and their nuclear receptor FXR: relevance for hepatobiliary and gastrointestinal disease. Biochem Biophys Acta 2010;1801:683–92
   PubMed Web of Science ®Google Scholar
• Ferris HA, Carroll RE, Lorimer DL, Benya RV. Location and characterization of the human GRP receptor expressed by gastrointestinal epithelial cells. Peptides 1997;18:663–72
   PubMedGoogle Scholar
• Qiao J, Kang JH, Ishola TA, et al. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. PNAS 2008;105:12891–6
   PubMedGoogle Scholar
• Carroll RE, Matkowskyj KA, Chakrabarti S, et al. Aberrant expression of gastrin-releasing peptide and its receptor by well differentiated colon cancers in humans. Am J Physiol 1999;276:G655–65
   Google Scholar
• Gershon, MD, Erde SM. The nervous system of the gut. Gastroenterology 1981;80:1571–94
   PubMed Web of Science ®Google Scholar
• McLean PG, Coupar IM. Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5-HT4-like receptors. Br J Pharmacol 1996;117:238–9
   PubMed Web of Science ®Google Scholar
• Gale JD, Grossman CJ, Whitehead JWF, et al. GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor. Br J Pharmacol 1994;111:332–8
   PubMed Web of Science ®Google Scholar
• Eglen RM, Swank SR, Walsh LKM, Whiting RL. Characterization of 5-HT 3 and 'atypical' 5-HT receptors mediating guinea-pig ileal contractions in vitro. Br J Pharmacol 1990;101:513–20
   PubMed Web of Science ®Google Scholar
• Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215–44
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Y. Growth inhibition of insulin-like growth factor I receptor monoclonal antibody to human colorectal cancer cells. Cancer Invest 2008;26:230–6
   PubMed Web of Science ®Google Scholar
• Adachi Y, Lee CT, Coffee K, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002;123:1191–204
   PubMed Web of Science ®Google Scholar
• Duerr RH, Barmada MM, Zhang L, et al. Linkage and association between inflammatory bowel disease and a locus on chromosome 12. Am J Hum Genet 1998;63:95–100
   PubMed Web of Science ®Google Scholar
• Jones DC, Edgar RS, Ahmad T, et al. Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immun 2006;7:576–82
   PubMed Web of Science ®Google Scholar
• Huanchun Z, Agnieszka B, Raluca R, et al. Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Krüppel-like factor 5. J Biol Chem 2007;25:15541–9
   Google Scholar
• Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582–91
   PubMed Web of Science ®Google Scholar
• Umezu-Goto M, Kishi Y, Taira A. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002;158:227–33
   PubMed Web of Science ®Google Scholar
• Shida D, Kitayama J, Yamaguchi H. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 2003;63:1706–11
   PubMed Web of Science ®Google Scholar
• Shida D, Watanabe T, Aoki J. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 2004;84:1352–62
   PubMedGoogle Scholar
• Gilman A. G proteins and dual control of adenylate cyclase. Cell 1984;36:577–79
   PubMed Web of Science ®Google Scholar
• Yang WL, Frucht H. Cholinergic receptor up-regulates COX-2 expression and prostaglandin E2 production in colon cancer cells. Carcinogenesis 2000;21:1789–93
   PubMed Web of Science ®Google Scholar
• Cheng K, Raufman JP. Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. Biochem Pharmacol 2005;70:1035–47
   PubMed Web of Science ®Google Scholar
• Frucht H, Gazdar AF, Park JA, et al. Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells. Cancer Res 1992;52:1114–22
   PubMed Web of Science ®Google Scholar
• Cheng K, Xie G, Raufman JP. Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol 2007;73:1001–12
   Google Scholar
• Raufman JP, Chen Y, Cheng K, et al. Selective interaction of bile acids with muscarinic receptors: a case of molecular mimicry. Eur J Pharmacol 2002;457:77–84
   PubMed Web of Science ®Google Scholar
• Allen JM, Adrian TE, Polak JM, Bloom SR. Neuropeptide Y in the adrenal gland. J Auton Nerv Syst 1983;9:559–63
   PubMedGoogle Scholar
• Solomon TE. Pancreatic polypeptides, peptide YY, and neuropeptide Y family of regulatory peptides. Gastroenterology 1985;88:838–44
   Google Scholar
• Tough IR, Forbes S,Tolhurst R, et al. Endogenous peptide YY and neuropeptide Y inhibit colonic ion transport, contractility and transit differentially via Y1 and Y2 receptors. Br J Pharmacol 2011;164:471–84
   Google Scholar
• Peaire AE, Krantis A, Staines WA. Distribution of the NPY receptor subtype Y1 within human colon: evidence for NPY targeting a subpopulation of nitrergic neurons. J Autonomic Nervous Syst 1997;67:168–75
   Google Scholar
• Wang XL, Sara MJ, Wang Q, Mark Evers B. Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers. Mol Cancer Ther 2010;9:2389–98
   PubMed Web of Science ®Google Scholar
• Tatsuta M, Iishi H, Baba M, Taniguchi H. Enhancement by neurotensin of experimental carcinogenesis induced in rat colon by azoxymethane. Br J Cancer 1990;62:368–71
   Google Scholar
• Summers AE, Whelan CJ, Parson ME. Nicotinic acetylcholine receptor subunits and receptor activity in the epithelial cell line HT29. Life Sci 2003;72:2091–4
   Google Scholar
• Wong HP, Yu L, Lam EK, et al. Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol Appl Pharmacol 2007;221:261–7
   PubMed Web of Science ®Google Scholar
• Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Rev 2005;48:420–7
   PubMed Web of Science ®Google Scholar
• Cheng K, Samimi R, Xie G, et al. Acetylcholine release by human colon cancer cells mediates autocrine stimulation of cell proliferation. Am J Physiol Gastrointest Liver Physiol 2008;295:G591–7
   Web of Science ®Google Scholar
• Pettersson A, Nilsson L, Nylund G, et al. Is acetylcholine an autocrine/paracrine growth factor via the nicotinic α7-receptor subtype in the human colon cancer cell line HT-29? Eur J Pharmacol 2009;609:27–33
   PubMed Web of Science ®Google Scholar
• Guy RS, Barry CP. Expression of notch receptors and ligands in the adult gut. J Histochem Cytochem 2004;52:509–16
   Google Scholar
• Zagon IS, McLaughlin PJ. The role of endogenous opioids and opioid receptors in human and animal cancers. In: Plotnikoff NP, Murgo AJ, Faith RE, Wybran J, eds. Stress and immunity. Caldwell, NJ: CRC Press; 1991: 343–56
   Google Scholar
• Hytreka SD, McLaughlinb PJ, Langa CM, Zagonb LS. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Lett 1996;101:159–64
   Google Scholar
• De Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322–7
   PubMed Web of Science ®Google Scholar
• Voisin T, Rouet-Benzineb P, Reuter N, Laburthe M. Orexins and their receptors: structural aspects and role in peripheral tissues. Cell Mol Life Sci 2003;60:72–87
   PubMedGoogle Scholar
• Martinasso G, Oraldi M, Trombetta A. Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines. PPAR Res 2007;2007:93416
   Google Scholar
• Dai Y, Wang WH. Peroxisome proliferator-activated receptor γ and colorectal cancer. World J Gastrointest Oncol 2010;15:159–64
   Google Scholar
• Lei P, Abdelrahim M, Cho SD, et al. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl) methanes inhibit colon cancer cell and tumor growth through activation of c-jun N-terminal kinase. Carcinogenesis 2008;29:1139–47
   PubMed Web of Science ®Google Scholar
• Burgermeister E, Tencer L, Liscovitch M. Peroxisome proliferator- activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 2003;22:3888–900
   PubMed Web of Science ®Google Scholar
• Shah YM, Ma X, Morimura K, et al. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol 2007;292:G1114–22
   PubMed Web of Science ®Google Scholar
• Teng S, Piquette-Miller M. Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br J Pharmacol 2007;151:367–76
   PubMed Web of Science ®Google Scholar
• Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006;130:341–8
   PubMed Web of Science ®Google Scholar
• Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994;35:675–8
   PubMed Web of Science ®Google Scholar
• Hiromichi F, Chen XB, John WR, Toshihiko M. Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells. Biochem Biophy Res Comm 2007;359:568–73
   Google Scholar
• Raman PS, Alves CS, Wirtz D, Konstantopoulos K. Single-molecule binding of CD44 to fibrin versus P-selectin predicts their distinct shear-dependent interactions in cancer. J Cell Sci 2011;124:1903–10
   Google Scholar
• Gallego D, Herna´ndez P, Clave M, Jime´nez M. P2Y1 receptors mediate inhibitory purinergic neuromuscular transmission in the human colon. Am J Physiol Gastrointest Liver Physiol 2006;291:G584–94
   PubMed Web of Science ®Google Scholar
• Jaafari N, Hua G, Adélaïde J, et al. Expression of the tachykinin receptor mRNAs in healthy human colon. Eur J Pharmacol 2008;599:121–5
   PubMed Web of Science ®Google Scholar
• Goode T, O’Connell J, Anton P, et al. Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut 2000;47:387–96
   Google Scholar
• Bougrine R, Masson C, Hatier R, et al. Receptor binding of transcobalamin II-cobalamin in human colon adenocarcinoma HT 29 cell line. J Nutr Biochem 1996;7:397–402
   Google Scholar
• Han Z, Slack RS, Li W, Papadopoulos V. Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression. J Recept Signal Transduct Res 2003;23:225–38
   PubMed Web of Science ®Google Scholar
• Ravagnan L, Marzo I, Costantini P, et al. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 1999;18:2537–46
   PubMed Web of Science ®Google Scholar
• Maaser K, Sutter AP, Krahn A, et al. Cell cycle-related signaling pathways modulated by peripheral benzodiazepine receptor ligands in colorectal cancer cells. Biochem Biophys Res Commun 2004;324:878–86
   PubMed Web of Science ®Google Scholar
• Gatza CE, Holtzhausen A, Kirkbride KC, et al. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia 2011;13:758–70
   Google Scholar
• Eppenberger M, Zlobec I, Baumhoer D, et al. Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. BMC Cancer 2010;10:1–10
   Google Scholar
• Evans SRT, Nolla J, Hanfelt J, et al. Vitamin D receptor expression as a predictive marker of biological behavior in human colorectal cancer. Clin Cancer Res 1998;4:1591–5
   Google Scholar
• Anderson MG, Nakane M, Ruan X, et al. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006;57:234–40
   PubMed Web of Science ®Google Scholar
• Larriba MJ, Martín-Villar E, García JM, et al. Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis 2009;30:1459–68
   PubMedGoogle Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579–91
   PubMed Web of Science ®Google Scholar
• O’Connell J, O’Sullivan GC, Collins JK, Shanahan F. The FAS counterattack: FAS-mediated T-cell killing by colon cancer cells expressing FAS ligand. J Exp Med 1996;184:1075–82
   PubMed Web of Science ®Google Scholar